Joel Greenblatt’s Kyntra Bio KYNB Stock Holding History

Joel Greenblatt’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-430	Closed	-$114K	–	1199
2022 Q2	$114K	Buy	+430	New	+$110K	﹤0.01%	1076
2022 Q1	–	Sell	-1,567	Closed	-$552K	–	1163
2021 Q4	$552K	Buy	+1,567	New	+$488K	0.02%	736
2020 Q1	–	Sell	-1,304	Closed	-$1.4M	–	1112
2019 Q4	$1.4M	Sell	1,304 -1,936	-60%	-$1.98M	0.03%	555
2019 Q3	$3M	Buy	+3,240	New	+$3.56M	0.05%	380
2019 Q2	–	Sell	-494	Closed	-$672K	–	1184
2019 Q1	$672K	Buy	494 +318	+181%	+$431K	0.01%	770
2018 Q4	$204K	Buy	+176	New	+$198K	﹤0.01%	938
2017 Q1	–	Sell	-876	Closed	-$469K	–	1028
2016 Q4	$469K	Buy	+876	New	+$437K	0.01%	736
2016 Q1	–	Sell	-463	Closed	-$352K	–	1004
2015 Q4	$352K	Sell	463 -708	-60%	-$470K	﹤0.01%	740
2015 Q3	$642K	Buy	+1,171	New	+$709K	0.01%	692
2015 Q2	–	Sell	-1,638	Closed	-$1.28M	–	942
2015 Q1	$1.28M	Buy	+1,638	New	+$1.27M	0.01%	565

Other funds holding KYNB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Joel Greenblatt's KYNB Position: Q3 2022 in Review

Joel Greenblatt sold out of Kyntra Bio (KYNB) in Q3 2022, closing a stake of 430 shares — an estimated $114K sold.

Joel Greenblatt first reported a position in KYNB in Q1 2015 and held it in 10 quarters. The position peaked at $3M in Q3 2019. 152 funds tracked by Wall St. Rank hold KYNB as of Q3 2022.

Joel Greenblatt reported no remaining Kyntra Bio position as of Q3 2022 after selling out during the quarter.
Joel Greenblatt sold 430 Kyntra Bio shares in Q3 2022, an estimated $114K.
Joel Greenblatt first reported a position in Kyntra Bio in Q1 2015 and held it in 10 quarters.
Joel Greenblatt's Kyntra Bio position peaked at $3M in Q3 2019.
152 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2022.

Based on Gotham Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.